PeptideDB

TAT-Gap19 TFA

TAT-Gap19 TFA

CAS No.:

TAT-Gap19 TFA is a Cx mimetic peptide and a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

TAT-Gap19 TFA is a Cx mimetic peptide and a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibit the corresponding Cx43 GJC. TAT-Gap19 TFA can penetrate the BBB (blood-brain barrier) and reduce liver fibrosis in mice.

Physicochemical Properties


Molecular Formula C121H213F3N46O28
Molecular Weight 2817.27
Related CAS # TAT-Gap19;1507930-54-2
Appearance White to off-white solid powder
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment, avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vivo In 4-month-old C57Bl6 male mice, a single intravenous injection of TAT-Gap19 TFA (iv; 55 mg/kg) results in a notable immunological signal in the brain 24 hours later[1]. Mice treated with 100–200 mg thioacetamide (TAA)/kg body weight for eight weeks[2] showed dramatically reduced collagen deposition and lowed levels of α-SMA-positive cell area when given TAT-Gap19 TFA (1 mg/kg /day) via an osmotic pump implanted in the peritoneal cavity.
References

[1]. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes. Front Cell Neurosci. 2014 Oct 21;8:306.

[2]. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3):817.

[3]. Inhibition of astroglial connexin43 hemichannels with TAT-Gap19 exerts anticonvulsant effects in rodents. Glia. 2018 Aug;66(8):1788-1804.


Solubility Data


Solubility (In Vitro) H2O :~100 mg/mL (~35.50 mM)
Solubility (In Vivo) Solubility in Formulation 1: 100 mg/mL (35.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 0.3550 mL 1.7748 mL 3.5495 mL
5 mM 0.0710 mL 0.3550 mL 0.7099 mL
10 mM 0.0355 mL 0.1775 mL 0.3550 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.